ASTRAZENECA PLC shares fell 1.7% on May 1 after a United States regulatory panel rejected its experimental breast cancer treatment. The United Kingdom drugmaker faced the negative vote overnight following a review of the drug's clinical data. This rejection stalls a key oncology pipeline asset, pressuring growth targets for the firm's dominant cancer portfolio.

FDA Panel Rejects Experimental Treatment